Personalis shares rose after CMS expanded Medicare coverage for the company’s NeXT Personal minimal residual disease assay to include immunotherapy monitoring across late-stage solid tumors. The decision was described as supported by evidence from a study with Spain’s Vall d’Hebron Institute of Oncology showing sufficient sensitivity for ongoing surveillance and outcome prediction during immunotherapy. The assay had already gained Medicare coverage for recurrence monitoring in stage II–III breast cancer and stage I–III non-small cell lung cancer. Personalis said IO reimbursement could create additional upside beyond current guidance.